IMR Press / FBL / Volume 13 / Issue 6 / DOI: 10.2741/2843

Frontiers in Bioscience-Landmark (FBL) is published by IMR Press from Volume 26 Issue 5 (2021). Previous articles were published by another publisher on a subscription basis, and they are hosted by IMR Press on imrpress.com as a courtesy and upon agreement with Frontiers in Bioscience.

Open Access Article
Acid ceramidase inhibition: a novel target for cancer therapy
Show Less
1 Departments of Microbiology and Immunology, Medical University of South Carolina, Charleston, South Carolina, 29425 USA
2 Departments of Biochemistry and Molecular Biology, Medical University of South Carolina, Charleston, South Carolina, 29425 USA
3 Departments of Urology, Medical University of South Carolina, Charleston, South Carolina, 29425 USA
4 Cancer Gene Therapy Group, GKT Dental Institute, King's College London, SE5 9NU, UK
Academic Editor:Masatoshi Tagawa
Front. Biosci. (Landmark Ed) 2008, 13(6), 2293–2298; https://doi.org/10.2741/2843
Published: 1 January 2008
(This article belongs to the Special Issue Current gene therapy for cancer)
Abstract

During the last decade, sphingolipid deregulation, namely the balance between the pro-apoptotic molecule ceramide and the anti-apoptotic sphingolipid sphingosine-1-phosphate, has emerged as an important factor in cancer pathology and resistance to therapy. Thus, our research has been focused on developing drugs that are able to restore normal sphingolipid balance, precisely through increasing the levels of ceramide and decreasing sphingosine-1-phosphate. Particularly, inhibition of the ceramide metabolizing enzyme acid ceramidase, whose over-expression in cancer cells has been implicated in resistance to treatment, is proving to be an efficient and promising strategy. In this review, we consider our recent work with acid ceramidase inhibitors, in combination with radiation or gene therapy as a sensitizer that enhance cancer therapy.

Share
Back to top